



2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM

Pegfilgrastim Agents - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with fields for Patient Name, Prescriber Name, Member Number, Date of Birth, Line of Business, Address, City, State ZIP, Primary Phone, Fax, Phone, Office Contact, NPI, State Lic ID, and Specialty/facility name.

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Form with fields for Drug Name, Strength, and Directions / SIG.

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.

Q1. Will pegfilgrastim be used as primary prophylaxis against febrile neutropenia?

Yes No

Q2. Is the patient receiving myelosuppressive chemotherapy (attach documentation)?

Yes No

Q3. Is the patient at increased risk for febrile neutropenia (attach documentation)?

Yes No

Q4. Is the patient receiving dose-dense or high-dose chemotherapy (attach documentation)?

Yes No

Q5. Will pegfilgrastim be used as secondary prophylaxis against febrile neutropenia?

Yes No

Q6. Is the patient receiving myelosuppressive chemotherapy with a history of febrile neutropenia during a previous course of chemotherapy for which primary prophylaxis was not received (attach documentation)?



2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM

Pegfilgrastim Agents - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<p>Q7. For Ziextenzo Only: is there a diagnosis of hematopoietic subsyndrome of acute radiation syndrome with attached documentation of exposure to myelosuppressive doses of radiation?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q8. Will the patient's complete blood count with differential including absolute neutrophil count (ANC) be monitored?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q9. Requested Duration:</p> <p><input type="checkbox"/> 12 Months <input type="checkbox"/> Other:</p>	
<p>Q10. Additional Information:</p>	

Prescriber Signature

Date

2024 Medicare Prior Authorization Request